Stroke is said to be the second leading cause of death worldwide after heart disease. To prevent the death of neurons in the ...

Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones H4R3 ...

In this Review, we summarize the molecular functions of protein lysine methylation and its involvement in human cancer, with a particular focus on lysine methylation of non-histone proteins.

The study “Identification of SARS CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of the nsp14 RNA Cap Methyltransferase” is available as a preprint on the bioRxiv ...

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer ...

Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing TNG462 in combination with Revolution Medicines' daraxonrasib or zoldonrasib for methylthioadenosine phosphorylase ...

Researchers have develop first-in-class inhibitors against ASH1L, a key protein in the development and progression of leukemia.

Amgen Inc. has described tricyclic-amido-bicyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

A recent study posted to bioRxiv * identified inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-structural protein 14 (Nsp14).

Researchers have found that blocking a specific protein could increase tumor sensitivity to treatment with PARP inhibitors. Their work suggests combining treatments could lead to improved therapy ...

Researchers have develop first-in-class inhibitors against ASH1L, a key protein in the development and progression of leukemia.

Neuroscience Kinase inhibitor makes neurons release toxic protein aggregates Researchers, biotech companies hope to use finding to treat ALS by Laurel Oldach ...